Tg Therapeutics (TGTX) Amortizatization of Intangibles (2013 - 2026)
Tg Therapeutics (TGTX) posted quarterly Amortizatization of Intangibles of $23000.0 for Q1 2022, down 81.89% year-over-year from $127000.0 in Q1 2021, and down 76.04% quarter-over-quarter from $96000.0 in Q4 2021.
Analysis
Tg Therapeutics (TGTX) Amortizatization of Intangibles (2013 - 2026) Analysis & Trends
Tg Therapeutics' Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at $23000.0 for Q1 2022.
- In Q1 2022, Amortizatization of Intangibles fell 81.89% year-over-year to $23000.0; the TTM figure through Mar 2022 stood at $413000.0 (up 603.66% YoY), while the FY2021 annual figure was $517000.0, changed N/A from the prior year.
- Amortizatization of Intangibles for Q1 2022 stood at $23000.0, down from $96000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $155000.0 in Q2 2021, with the low at -$75000.0 in Q1 2019.
- The 4-year median for Amortizatization of Intangibles is -$4500.0 (2018), against an average of $17666.7.
- Peak annual rise in Amortizatization of Intangibles reached 42.86% in 2019, while the deepest fall reached 3850.0% in 2019.
- Tg Therapeutics' Amortizatization of Intangibles stood at -$68000.0 in 2018, then grew by 11.76% to -$60000.0 in 2019, then surged by 260.0% to $96000.0 in 2021, then plunged by 76.04% to $23000.0 in 2022.
- Business Quant data shows TGTX's Amortizatization of Intangibles at $23000.0 in Q1 2022, $96000.0 in Q4 2021, and $139000.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Tg Therapeutics | 7.97 Bn | 7.29 Bn | 199.14 Mn | 441,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 441,000.00 |
| Mar 31, 2026 | 573,000.00 |
| Dec 31, 2025 | 432,000.00 |
| Sep 30, 2025 | 431,000.00 |
| Jun 30, 2025 | 432,000.00 |
| Mar 31, 2025 | 453,000.00 |
| Dec 31, 2024 | 498,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Jun 30, 2024 | 498,000.00 |
| Mar 31, 2024 | 407,000.00 |
| Dec 31, 2023 | 490,000.00 |
| Sep 30, 2023 | 483,000.00 |
| Jun 30, 2023 | 499,000.00 |
| Mar 31, 2023 | 491,000.00 |
| Mar 31, 2022 | 23,000.00 |
| Dec 31, 2021 | 1.48 Mn |
| Sep 30, 2021 | 139,000.00 |
| Jun 30, 2021 | 155,000.00 |
| Mar 31, 2021 | 127,000.00 |
| Sep 30, 2019 | -60,000.00 |